These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 36983628)

  • 1. Prognostic Value of Soluble AXL in Serum from Heart Failure Patients with Preserved and Reduced Left Ventricular Ejection Fraction.
    Cristóbal H; Enjuanes C; Batlle M; Tajes M; Campos B; Francesch J; Moliner P; Farrero M; Andrea R; Ortiz-Pérez JT; Morales A; Sabaté M; Comin-Colet J; García de Frutos P
    J Pers Med; 2023 Feb; 13(3):. PubMed ID: 36983628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of plasma sAXL in patients with heart failure: insights from the DRAGON-HF trial.
    Liu Y; Wang X; Pan X; Ma T; Xu Y; Fen Q; Nijiati M; Chi C; Su Y; Zhang X; Xu D
    ESC Heart Fail; 2023 Feb; 10(1):661-672. PubMed ID: 36436827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of serum levels of high sensitivity troponin T, galectin-3 and C-terminal propeptide of type I procollagen at long term follow-up in heart failure patients with reduced ejection fraction: Comparison with soluble AXL and BNP.
    Batlle M; Campos B; Farrero M; Cardona M; González B; Castel MA; Ortiz J; Roig E; Pulgarín MJ; Ramírez J; Bedini JL; Sabaté M; García de Frutos P; Pérez-Villa F
    Int J Cardiol; 2016 Dec; 225():113-119. PubMed ID: 27718443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Five-year mortality of heart failure with preserved, mildly reduced, and reduced ejection fraction in a 4880 Chinese cohort.
    Chen S; Huang Z; Liang Y; Zhao X; Aobuliksimu X; Wang B; He Y; Kang Y; Huang H; Li Q; Yao Y; Lu X; Qian X; Xie X; Liu J; Liu Y
    ESC Heart Fail; 2022 Aug; 9(4):2336-2347. PubMed ID: 35437939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarkers for characterization of heart failure - Distinction of heart failure with preserved and reduced ejection fraction.
    Sinning C; Kempf T; Schwarzl M; Lanfermann S; Ojeda F; Schnabel RB; Zengin E; Wild PS; Lackner KJ; Munzel T; Blankenberg S; Wollert KC; Zeller T; Westermann D
    Int J Cardiol; 2017 Jan; 227():272-277. PubMed ID: 27838133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relation of Renal Function with Left Ventricular Systolic Function and NT-proBNP Level and Its Prognostic Implication in Heart Failure with Preserved versus Reduced Ejection Fraction: an analysis from the Korean Heart Failure (KorHF) Registry.
    Park CS; Park JJ; Oh IY; Yoon CH; Choi DJ; Park HA; Kang SM; Yoo BS; Jeon ES; Kim JJ; Cho MC; Chae SC; Ryu KH; Oh BH;
    Korean Circ J; 2017 Sep; 47(5):727-741. PubMed ID: 28955391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognosis and NT-proBNP in heart failure patients with preserved versus reduced ejection fraction.
    Salah K; Stienen S; Pinto YM; Eurlings LW; Metra M; Bayes-Genis A; Verdiani V; Tijssen JGP; Kok WE
    Heart; 2019 Aug; 105(15):1182-1189. PubMed ID: 30962192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Left atrial volume and left ventricular mass indices in heart failure with preserved and reduced ejection fraction.
    Gehlken C; Screever EM; Suthahar N; van der Meer P; Westenbrink BD; Coster JE; Van Veldhuisen DJ; de Boer RA; Meijers WC
    ESC Heart Fail; 2021 Aug; 8(4):2458-2466. PubMed ID: 34085774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growth differentiation factor 15 in heart failure with preserved vs. reduced ejection fraction.
    Chan MM; Santhanakrishnan R; Chong JP; Chen Z; Tai BC; Liew OW; Ng TP; Ling LH; Sim D; Leong KT; Yeo PS; Ong HY; Jaufeerally F; Wong RC; Chai P; Low AF; Richards AM; Lam CS
    Eur J Heart Fail; 2016 Jan; 18(1):81-8. PubMed ID: 26497848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world clinical diagnostics of heart failure patients with reduced or preserved ejection fraction.
    Huusko J; Purmonen T; Toppila I; Lassenius M; Ukkonen H
    ESC Heart Fail; 2020 Jun; 7(3):1039-1048. PubMed ID: 32187879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prognostic value of N-terminal B-type natriuretic peptide on all-cause mortality in heart failure patients with preserved ejection fraction].
    Cao J; Jin XJ; Zhou J; Chen ZY; Xu DL; Yang XC; Dong W; Li LW; Luo J; Chen L; Fu M; Zhou JM; Ge JB
    Zhonghua Xin Xue Guan Bing Za Zhi; 2019 Nov; 47(11):875-881. PubMed ID: 31744276
    [No Abstract]   [Full Text] [Related]  

  • 12. Empagliflozin in Heart Failure With Predicted Preserved Versus Reduced Ejection Fraction: Data From the EMPA-REG OUTCOME Trial.
    Savarese G; Uijl A; Lund LH; Anker SD; Asselbergs F; Fitchett D; Inzucchi SE; Koudstaal S; Ofstad AP; Schrage B; Vedin O; Wanner C; Zannad F; Zwiener I; Butler J
    J Card Fail; 2021 Aug; 27(8):888-895. PubMed ID: 34364665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population.
    Cheng RK; Cox M; Neely ML; Heidenreich PA; Bhatt DL; Eapen ZJ; Hernandez AF; Butler J; Yancy CW; Fonarow GC
    Am Heart J; 2014 Nov; 168(5):721-30. PubMed ID: 25440801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High serum fibroblast growth factor 21 levels were related to the prognosis and ventricular remodeling of heart failure patients with mildly reduced and reduced ejection fraction.
    Fan L; Gu L; Yao Y; Ma G
    Perfusion; 2024 Mar; 39(2):285-293. PubMed ID: 36321746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating biomarkers of distinct pathophysiological pathways in heart failure with preserved vs. reduced left ventricular ejection fraction.
    Sanders-van Wijk S; van Empel V; Davarzani N; Maeder MT; Handschin R; Pfisterer ME; Brunner-La Rocca HP;
    Eur J Heart Fail; 2015 Oct; 17(10):1006-14. PubMed ID: 26472682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Limited value of NT-proBNP as a prognostic marker of all-cause mortality in patients with heart failure with preserved and mid-range ejection fraction in primary care: A report from the swedish heart failure register.
    Eriksson B; Wändell P; Dahlström U; Näsman P; Lund LH; Edner M
    Scand J Prim Health Care; 2019 Dec; 37(4):434-443. PubMed ID: 31724475
    [No Abstract]   [Full Text] [Related]  

  • 17. Prevalence and Prognostic Implications of Longitudinal Ejection Fraction Change in Heart Failure.
    Savarese G; Vedin O; D'Amario D; Uijl A; Dahlström U; Rosano G; Lam CSP; Lund LH
    JACC Heart Fail; 2019 Apr; 7(4):306-317. PubMed ID: 30852236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of NT-proBNP in heart failure with preserved versus reduced EF.
    Kang SH; Park JJ; Choi DJ; Yoon CH; Oh IY; Kang SM; Yoo BS; Jeon ES; Kim JJ; Cho MC; Chae SC; Ryu KH; Oh BH;
    Heart; 2015 Dec; 101(23):1881-8. PubMed ID: 26319121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AXL receptor tyrosine kinase is increased in patients with heart failure.
    Batlle M; Recarte-Pelz P; Roig E; Castel MA; Cardona M; Farrero M; Ortiz JT; Campos B; Pulgarín MJ; Ramírez J; Pérez-Villa F; García de Frutos P
    Int J Cardiol; 2014 May; 173(3):402-9. PubMed ID: 24681018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ankle-brachial index and incident heart failure with reduced versus preserved ejection fraction: The Multi-Ethnic Study of Atherosclerosis.
    Prasada S; Shah SJ; Michos ED; Polak JF; Greenland P
    Vasc Med; 2019 Dec; 24(6):501-510. PubMed ID: 31480898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.